Clinical Evaluation of Amoscanate in Healthy Male Volunteers

Theresa A. Shapiro

Search for other papers by Theresa A. Shapiro in
Current site
Google Scholar
PubMed
Close
,
Joab B. Were

Search for other papers by Joab B. Were in
Current site
Google Scholar
PubMed
Close
,
Paul TalalayDepartment Pharmacology and Experimental Therapeutics

Search for other papers by Paul Talalay in
Current site
Google Scholar
PubMed
Close
,
Ernest Bueding

Search for other papers by Ernest Bueding in
Current site
Google Scholar
PubMed
Close
,
Laura RoccoDivision of Clinical Pharmacology, Department of Medicine, and

Search for other papers by Laura Rocco in
Current site
Google Scholar
PubMed
Close
,
Kwame DansoDivision of Clinical Pharmacology, Department of Medicine, and

Search for other papers by Kwame Danso in
Current site
Google Scholar
PubMed
Close
,
Robert MassofDepartments of Opthalmology

Search for other papers by Robert Massof in
Current site
Google Scholar
PubMed
Close
,
Richard GreenDepartments of Opthalmology

Search for other papers by Richard Green in
Current site
Google Scholar
PubMed
Close
,
E. David MellitsDepartments of Pediatrics, The Johns Hopkins University, Baltimore, Maryland 21205

Search for other papers by E. David Mellits in
Current site
Google Scholar
PubMed
Close
, and
Paul S. Lietman

Search for other papers by Paul S. Lietman in
Current site
Google Scholar
PubMed
Close
Restricted access

Single oral doses of amoscanate (4-isothiocyanato-4′-nitrodiphenylamine), an experimental antiparasitic agent, are highly effective in animals against the four major species of schistosomes which infect humans. Two prospective, randomized, double blinded, placebo controlled Phase I studies were designed to evaluate the tolerance and safety of the 5% aqueous suspension of 2-µ particles of amoscanate administered to healthy male volunteers. In addition to routine safety monitoring, particular attention was directed toward detecting hepatic, neurological, cardiovascular or ocular toxicity. Three of four men who received 3.5 mg/kg of amoscanate developed mild, reversible hepatotoxicity, which could not be unequivocably attributed to the drug. In the second study, of 1 mg/kg amoscanate, there was no statistically significant evidence of hepatotoxicity, although 1 of 12 drug recipients developed transient liver chemistry changes. Despite intensive monitoring, there was no evidence in either study of significant symptomatic complaints, or of neurological, cardiovascular or ocular toxicity. No mutagenic activity attributable to amoscanate was detectable in the urine. These results suggest that this formulation of amoscanate, at 1 mg/kg, is sufficiently well tolerated and safe to justify evaluation for efficacy in patients with schistosomiasis.

Author Notes

Deceased.

Save